In a Market of Entrenched, Effective, and Mostly Generic Therapies, Where Do Physicians and Payers Identify Areas for Differentiation? The prevalence of Parkinson’s disease (PD) will approach 3…
Compared with Current and Emerging Non-Insulin Therapies, Does Metformin’s Clinical Profile Justify Its Dominant Position in Recommended Treatment Guidelines? Affecting 30 million people in the…
How Will U.S. Payer and Prescriber Attitudes Shape This Competitive Market? The treatment of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)…
This report leverages physician insights, as well as a year’s worth of patient chart data, to provide the most up-to-date information about dialysis patient care in the EU5, including patient…
Which Attributes, in the Eyes of Oncologists and Payers, Will Allow Emerging Therapies to Gain Traction in a Market Experiencing Generic Erosion? Drug development for advanced/metastatic, hormone-…
LaunchTrends: Keytruda (Wave 2) is the second in a series of syndicated reports designed to track the physician perception, uptake, and competitive environment of the malignant melanoma drug…
How Are Novel Therapies Differentiated from Current Treatment Options in This Highly Genericized Market? Acute heart failure (AHF) is one of the leading causes of hospitalization in the developed…
TreatmentTrends®: Breast Cancer Q2 2015 (US) in the first in a series of reports that examine current trends in the management of advanced/metastatic breast cancer from the perspective of medical…
Securing Market Share and Payer Acceptance in Increasingly Crowded and Segmented Markets in Brazil and Mexico Small molecule therapies offer specific targeting of the aberrant cellular signaling…
LaunchTrends: Ibrance (Wave 1) is the first in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched breast cancer…
LaunchTrends®: Lemtrada (US) is a four-wave syndicated report series that specifically tracks the introduction of Genzyme’s Lemtrada (alemtuzumab), a potent, intravenous disease-modifying…
Probing Prescriber Preferences and Payer Strategies for Current and Emerging Agents in the EU5 Nearly 800,000 individuals were diagnosed with opioid addiction in the five major European markets…
Which Efficacy and Safety Achievements Will Differentiate Emerging Therapies in a Crowded Market Filled with Efficacious Drugs? Nine biologics are approved to treat rheumatoid arthritis (RA),…
A Survey of Psychiatrists and Interviews with Payers in the EU5 Despite being a leading preventable cause of morbidity and mortality in Europe, alcohol addiction is tremendously underdiagnosed and…
Pulmonary arterial hypertension (PAH) is a severe and debilitating disease with rapid progression and high rates of mortality. If left untreated, life expectancy is less than three years; even…
